Why Agenus’ Stock Surges Past 200-Day MA Despite Negative P/E
Check out how Agenus Inc. defied expectations in Q1, breaking its 200‑day MA and showing a positive EPS amid a -1211.76 P/E—insider confidence, analyst split, and institutional interest suggest a possible biotech turnaround.
2 minutes to read
